Impact of time from diagnosis to chemotherapy in advanced gastric cancer: A Propensity Score Matching Study to Balance Prognostic Factors

Table 2 Chemotherapy regimens and responses of patients with advanced gastric cancer

Characteristics	Total	Early WT	Elective WT	P value
No.	110	46	64
Chemotherapy; combination	76, 70%	27, 59%	49, 78%	0.0371
Agents
5-FU	104	40, 85%	64, 93%	0.3532
Platinum	79	26, 55%	53, 77%	0.0100
Irinotecan	1	1, 2.1%	0, 0%	1.0000
Taxane	14	8, 17%	6, 8.7%	0.2460
Trastuzumab	19	9, 19%	10, 14%	0.6110
Ramucirumab	1	0, 0%	1, 1.5%	0.4072
Response to first-line chemotherapy
CR	1, 0.91%	0, 0%	1, 1.6%	0.1721
PR	23, 20.9%	7, 15.2%	16, 25%
SD	47, 42.7%	17, 37.0%	30, 46.9%
PD	16, 14.6%	10, 21.7%	6, 9.4%
NE	23, 20.9%	12, 26.1%	11, 17.2%
RR	24, 21.8%	7, 15.2%	17, 26.6%
DCR	71,64.5%	24, 52.8%	47, 73.5%
Second-line chemotherapy, yes1	54, 63.5%	24, 58.5%	30, 68.2%	0.3770

¹Twenty-five patients were not evaluated (during first-line chemotherapy). WT: Waiting time; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NE: Not evaluated; RR: Response rate; DCR: Disease control rate.